Viatris Inc 8K

Viatris Inc. reported Q2 2026 results with solid revenue and adjusted earnings growth, raised full-year 2026 guidance, executed asset sales and capital returns, but recorded a GAAP loss tied to the planned Tyrvaya rights sale and flagged supply disruptions from its Nashik facility remediation that are expected to modestly impact second-half revenues.

On August 6, 2026, Viatris Inc. reported its second-quarter 2026 financial results, highlighting total revenues of $3.8 billion (up 5% year over year), adjusted EBITDA of $1.2 billion (up 10%), and an adjusted EPS of $0.69, while posting a U.S. GAAP net loss of $119 million driven largely by a $177.8 million non-cash impairment tied to the planned sale of Tyrvaya product rights. The company announced a definitive agreement in August to sell global rights to Tyrvaya to Harrow, Inc. for $30 million upfront plus up to $70 million in contingent milestone payments, completed the July sale of its equity position in Biocon Limited for approximately $380 million (finalizing about $780 million in total monetization of its Biocon Biologics stake), and continued to advance its pipeline with FDA approvals for Gwyn Lo (a low-dose combined hormonal contraceptive patch) and a generic ferric carboxymaltose injection, as well as positive Phase 3 data for VR-205 (Nefecon) in Japanese IgA nephropathy patients. Viatris also disclosed operational challenges at its Nashik, India oral solid dose plant following a February fire and subsequent Form 483 observations in May, noting ongoing remediation and intermittent disruptions that are expected to reduce second-half 2026 revenues by approximately $100–$150 million, while at the same time raising the midpoints of its full-year 2026 guidance for total revenues, adjusted EBITDA, adjusted EPS, and free cash flow, repaying roughly $900 million of maturing debt (refinanced with €650 million of 4.25% notes due 2033), returning about $550 million to shareholders (including $270 million of share repurchases through early August), and reducing its gross leverage ratio to 2.9x.

Filing Facts

CIK

1792044

Ticker

VTRS

Form

8K

Source Type

fda

Accession

0001792044-26-000037

Alert Tier

7